Bicycle Therapeutics plc (FRA:50BA)

Market Cap	316.18M -63.0%
Revenue (ttm)	24.15M -23.2%
Net Income	-213.64M
EPS	-3.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20
Average Volume	n/a
Open	4.360
Previous Close	4.280
Day's Range	4.360 - 4.500
52-Week Range	4.220 - 11.400
Beta	n/a
RSI	34.27
Earnings Date	Feb 20, 2026

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 305
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 50BA

Financial Performance

In 2024, Bicycle Therapeutics's revenue was $35.28 million, an increase of 30.76% compared to the previous year's $26.98 million. Losses were -$169.03 million, -6.44% less than in 2023.

Financial numbers in USD